Tempest Therapeutics, Inc.
TPST
$10.03
$0.6757.22%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
8/13/2025
-
GuruFocus
8/11/2025
-
The Fly
8/11/2025
-
SeekingAlpha.com: All News
8/11/2025
-
Globe Newswire
8/4/2025
-
TipRanks Financial Blog
6/30/2025
-
The Fly
6/30/2025
-
Globe Newswire
6/12/2025
-
TipRanks Financial Blog
6/12/2025
-
CNW Group - News Releases
6/12/2025
-
PR Newswire
6/11/2025
-
GuruFocus
6/11/2025
-
Globe Newswire
6/6/2025
-
TipRanks Financial Blog
6/6/2025
-
Zacks Investment Research
6/5/2025
-
The Fly
6/5/2025
-
Globe Newswire
6/4/2025
-
Ticker Report
5/13/2025
-
The Fly
5/13/2025
-
Globe Newswire
4/28/2025
-
Globe Newswire
4/21/2025
-
GuruFocus
4/21/2025
-
The Fly
4/21/2025
-
Globe Newswire
4/21/2025
-
FierceBiotech.com - Biotech
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, August 11, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
415 798 8589
Address
2000 Sierra Point Parkway
Brisbane, CA 94005
Brisbane, CA 94005
Country
Year Founded
--
Business Description
Sector
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral...
more